Zydus Lifesciences Ltd.

•

zyduscadila.comBSE: 532321NSE: ZYDUSLIFE

Market Cap₹ 1,12,618 Cr.

Current Price

High / Low₹ 1,205 / 836

Stock P/E32.0

Book Value₹ 230

Price to Book3.70

Dividend Yield0.09 %

ROCE16.0 %

ROE15.9 %

Face Value₹ 1

Add ratio to table

ABOUT

KEY POINTS

Revenue Breakup Mar 2026 • Pharmaceuticals: 82.6% • Consumer Products: 14.6% • Medical Technologies: 2.9%

AI Sector View

AI GENERATED

Healthcare

Buy

This stance relies on proxies and positioning because no direct pharma-export or healthcare operating series exists in the dataset. The depreciated currency at 95.23 (Sep/26) can support export earnings, inflation at 4.45% (Jul/26) is manageable for a defensive sector, and consumer spending remains large at INR 44743 billion (Jun/26). Strong FPI inflow of INR 10620 crore over 3 months to 2026-08-31 from INR -11381 crore in the prior 3 months adds a real sector-specific tailwind, but confidence stays capped because the fundamental drivers are indirect proxies.

Confidence

50%

View full sector analysis →

PROS

Company has a good return on equity (ROE) track record: 3 Years ROE 23.5%
Company has a healthy return on capital (ROCE) of 23.3%
Company comfortably covers its interest (10.1x coverage)
Company generates healthy free cash flow
Company has a consistent dividend-paying track record
Company maintains a comfortable, low leverage position

CONS

A large part of profit comes from other income (66.1% of PBT)
Recent results are weak - TTM profit is down 27.2% versus prior year
Receivables are growing faster than sales - a possible quality concern
Poor cash conversion - profits are not backed by operating cash flow (CFO/PAT 0.58x)
Working capital days have increased from 180 to 337 days
Operating margins have contracted to 23.4% from 34.4%

* The pros and cons are machine generated based on quantitative rules.

Peer comparison

HealthcareHealthcarePharmaceuticals & Drugs

Part ofNIFTY NEXT 50 NIFTY PHARMA NIFTY100 QUALTY30 NIFTYLARGEMIDCAP250 NIFTY100 EQL WGT

S.No.	Name
1.	SUNPHARMA	1868.50	37.06	448315.74	0.86	2901.23	26.53	15299.88	10.98	19.11	28.81
2.	DIVISLAB	9482.75	86.06	251737.22	0.32	902.00	65.50	3080.00	27.80	21.51	40.75
3.	TORNTPHARM	4931.90	86.01	187593.62	0.77	566.00	3.28	4921.00	57.32	19.27	33.81
4.	ZYDUSLIFE	1129.00	24.95	112618.18	0.09	990.20	-34.90	8017.00	23.97	21.39	24.54
5.	CIPLA	1368.00	32.79	110515.04	0.95	785.55	-39.18	7119.28	4.13	16.00	16.73
6.	LAURUSLABS	1933.25	95.54	104455.86	0.10	362.07	123.94	2026.31	29.10	18.20	31.50
7.	AUROPHARMA	1690.00	26.19	97238.86	0.24	1032.03	25.22	9150.35	17.44	12.76	20.54
8.	LUPIN	2092.00	17.30	95660.02	0.86	1416.98	16.01	8276.89	34.28	28.86	29.59
9.	DRREDDY	1143.20	29.61	95420.61	0.70	435.60	-69.10	8099.80	-5.21	13.75	10.63
10.	MANKIND	2266.00	45.82	93596.02	0.04	574.09	29.12	4030.59	12.89	13.24	26.30
11.	GLENMARK	2439.55	38.29	68850.12	0.10	482.83	927.88	4018.48	31.35	20.35	20.03
12.	BIOCON	395.00	129.97	64372.92	0.13	136.80	53.36	4336.00	10.89	3.26	19.54

Detailed Comparison with:

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	2,870	2,050	2,225	3,173	4,035	2,512	2,409	5,634	2,496	2,809	2,207	3,565	2,872
	1,815	1,597	1,672	1,771	1,787	1,733	1,867	2,047	2,003	2,115	2,085	2,400	2,540
Operating Profit	1,055	453	553	1,402	2,248	779	542	3,587	493	694	123	1,165	332
OPM %	36.77%	22.12%	24.85%	44.18%	55.71%	31.02%	22.48%	63.67%	19.75%	24.70%	5.55%	32.68%	11.56%
	82	621	107	360	107	381	78	185	157	937	414	1,036	124
Interest	90	91	104	106	115	96	97	155	138	114	116	116	103
Depreciation	121	125	128	131	131	134	132	128	130	136	144	151	152
Profit before Tax	1,012	968	574	1,685	2,234	1,039	497	3,675	475	1,444	352	2,111	456
Tax %	22.87%	16.85%	21.57%	16.60%	23.85%	24.01%	5.35%	23.43%	18.99%	19.88%	15.86%	18.43%	25.48%
Net Profit	781	805	450	1,405	1,701	790	471	2,814	385	1,157	296	1,722	340
	7.71	7.96	4.45	13.89	16.90	7.85	4.68	27.96	3.82	11.49	2.95	17.11	3.38

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
	3,231	5,810	6,037	6,347	7,780	7,837	8,732	10,819	15,116	11,484	11,453
	2,910	4,164	4,413	4,928	5,473	6,066	6,553	6,838	7,590	8,787	9,140
Operating Profit	321	1,646	1,625	1,420	2,307	1,771	2,178	3,981	7,527	2,697	2,313
OPM %	9.94%	28.34%	26.91%	22.37%	29.66%	22.60%	24.95%	36.79%	49.79%	23.48%	20.20%
	599	208	566	801	-97	6	621	1,154	931	2,729	2,511
Interest	27	64	92	234	71	135	278	391	489	483	448
Depreciation	251	293	358	429	451	479	489	504	524	561	583
Profit before Tax	642	1,497	1,741	1,558	1,688	1,164	2,032	4,240	7,445	4,382	4,363
Tax %	-3.07%	27.14%	17.31%	13.10%	12.57%	26.29%	24.75%	18.83%	22.43%	18.76%	19.44%
Net Profit	662	1,091	1,440	1,354	1,476	858	1,529	3,442	5,775	3,560	3,515
EPS	6.47	10.66	14.51	13.80	14.42	8.38	15.06	34.21	57.40	35.39	—
Dividend Payout %	49.51%	32.86%	24.89%	26.48%	24.28%	29.84%	39.71%	8.77%	19.16%	2.83%	—

COMPOUNDED SALES GROWTH

10 Years:: 5%
5 Years:: 8%
3 Years:: 10%

COMPOUNDED PROFIT GROWTH

10 Years:: 6%
5 Years:: 19%
3 Years:: 33%

STOCK PRICE CAGR

10 Years:: 11%
5 Years:: 15%
3 Years:: 21%
1 Year:: 8%

RETURN ON EQUITY

10 Years:: 16%
5 Years:: 18%
3 Years:: 24%
Last Year:: 16%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	102	102	102	102	102	102	101	101	101	101
	6,516	7,643	8,467	11,158	12,642	13,138	13,538	15,616	21,090	23,571
	2,902	2,704	3,476	3,052	3,318	2,173	4,762	6,202	5,912	6,957
Trade Payables	996	803	701	863	1,126	1,065	1,043	1,112	1,232	1,472
	1,316	1,997	2,328	2,981	2,898	3,447	3,641	4,466	8,703	6,910
Total Liabilities	11,832	13,249	15,074	18,156	20,086	19,925	23,086	27,496	37,037	39,011
	2,352	2,680	3,932	4,109	4,112	4,336	4,184	4,369	4,202	5,084
Capital Work in Progress	678	659	675	553	570	384	739	627	1,188	621
	3,924	3,618	4,195	6,404	6,471	5,118	4,879	7,283	11,492	11,478
	933	1,321	1,472	1,395	1,780	1,926	1,782	1,687	1,952	2,178
	0	0	0	0	0	0	0	4,740	8,162	8,495
Cash & Bank	17	184	112	385	154	303	248	414	144	734
	3,928	4,787	4,687	5,310	6,999	7,859	11,253	8,376	9,897	10,421
Total Assets	11,832	13,249	15,074	18,156	20,086	19,925	23,086	27,496	37,037	39,011

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	975	583	893	1,382	2,491	1,542	1,471	2,000	3,114	2,234
Cash from Investing	-2,480	28	-745	55	-2,714	586	-1,959	-1,832	-4,504	570
Cash from Financing	1,366	-149	65	-967	255	-1,710	827	-301	1,384	-2,580
	-247	167	-100	269	-231	149	-54	-132	-5	224

Ratios

Standalone Figures in Rs. Crores / View Consolidated

	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026

Shareholding Pattern

Numbers in percentages

	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	74.98	74.98	74.98	74.99	74.99	74.99	75.00	75.00	75.01
	5.59	7.52	7.53	7.31	7.13	7.34	7.06	6.95	6.88
	12.56	10.59	10.61	10.95	11.09	10.86	11.08	11.20	11.27
Government	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	6.79	6.85	6.84	6.68	6.74	6.80	6.85	6.86	6.83

Documents

Corporate disclosures, annual reports, credit ratings, and concall transcripts

2026-09-09

Copy of Newspaper Publication

2026-09-09 - Zydus Lifesciences Limited has informed the Exchange about Copy of Newspaper Publication

2026-09-05

General Updates

2026-09-05 - Zydus Lifesciences Limited has informed the Exchange about General Updates

2026-09-01

General Updates

2026-09-01 - Zydus Lifesciences Limited has informed the Exchange about General Updates

2026-08-31

Press Release

2026-08-31 - Zydus Lifesciences Limited has informed the Exchange regarding a press release dated August 31, 2026, titled "Zydus Announces Positive Topline Results from Completed EVIDENCES-X Phase II(b) Clinical Trial of Saroglitazar Mg in MASH".

2026-08-26

General Updates

2026-08-26 - Zydus Lifesciences Limited has informed the Exchange about General Updates

2026-08-25

General Updates

2026-08-25 - Zydus Lifesciences Limited has informed the Exchange about General Updates

2026-08-24

Updates

2026-08-24 - Zydus Lifesciences Limited has informed the Exchange regarding 'Disclosure under SEBI (Prohibition of Insider Trading) Regulations, 2015'.

2026-08-23

Investor Presentation

2026-08-23 - Zydus Lifesciences Limited has informed the Exchange about Investor Presentation

2026-08-21

General Updates

2026-08-21 - Zydus Lifesciences Limited has informed the Exchange about General Updates

News

Recent coverage and analyst commentary for ZYDUSLIFE

Loading news…

🤖

AI Stock Analyst

Zydus Lifesciences Ltd.

🔒

Sign in to Chat with AI

✨ Sign In to Chat

Free 5nance Account

Name

SUNPHARMA

1868.50

37.06

448315.74

0.86

2901.23

26.53

15299.88

10.98

19.11

28.81

DIVISLAB

9482.75

86.06

251737.22

0.32

902.00

65.50

3080.00

27.80

21.51

40.75

TORNTPHARM

4931.90

86.01

187593.62

0.77

566.00

3.28

4921.00

57.32

19.27

33.81

ZYDUSLIFE

1129.00

24.95

112618.18

0.09

990.20

-34.90

8017.00

23.97

21.39

24.54

CIPLA

1368.00

32.79

110515.04

0.95

785.55

-39.18

7119.28

4.13

16.00

16.73

LAURUSLABS

1933.25

95.54

104455.86

0.10

362.07

123.94

2026.31

29.10

18.20

31.50

AUROPHARMA

1690.00

26.19

97238.86

0.24

1032.03

25.22

9150.35

17.44

12.76

20.54

LUPIN

2092.00

17.30

95660.02

0.86

1416.98

16.01

8276.89

34.28

28.86

29.59

DRREDDY

1143.20

29.61

95420.61

0.70

435.60

-69.10

8099.80

-5.21

13.75

10.63

MANKIND

2266.00

45.82

93596.02

0.04

574.09

29.12

4030.59

12.89

13.24

26.30

GLENMARK

2439.55

38.29

68850.12

0.10

482.83

927.88

4018.48

31.35

20.35

20.03

BIOCON

395.00

129.97

64372.92

0.13

136.80

53.36

4336.00

10.89

3.26

19.54

Jun 2023

Sep 2023

Dec 2023

Mar 2024

Jun 2024

Sep 2024

Dec 2024

Mar 2025

Jun 2025

Sep 2025

Dec 2025

Mar 2026

Jun 2026

2,870

2,050

2,225

3,173

4,035

2,512

2,409

5,634

2,496

2,809

2,207

3,565

2,872

1,815

1,597

1,672

1,771

1,787

1,733

1,867

2,047

2,003

2,115

2,085

2,400

2,540

Operating Profit

1,055

453

553

1,402

2,248

779

542

3,587

493

694

123

1,165

332

OPM %

36.77%

22.12%

24.85%

44.18%

55.71%

31.02%

22.48%

63.67%

19.75%

24.70%

5.55%

32.68%

11.56%

621

107

360

107

381

185

157

937

414

1,036

124

Interest

104

106

115

155

138

114

116

103

Depreciation

121

125

128

131

134

132

128

130

136

144

151

152

Profit before Tax

1,012

968

574

1,685

2,234

1,039

497

3,675

475

1,444

352

2,111

456

Tax %

22.87%

16.85%

21.57%

16.60%

23.85%

24.01%

5.35%

23.43%

18.99%

19.88%

15.86%

18.43%

25.48%

Net Profit

781

805

450

1,405

1,701

790

471

2,814

385

1,157

296

1,722

340

7.71

7.96

4.45

13.89

16.90

7.85

4.68

27.96

3.82

11.49

2.95

17.11

3.38

Mar 2017

Mar 2018

Mar 2019

Mar 2020

Mar 2021

Mar 2022

Mar 2023

Mar 2024

Mar 2025

Mar 2026

TTM

3,231

5,810

6,037

6,347

7,780

7,837

8,732

10,819

15,116

11,484

11,453

2,910

4,164

4,413

4,928

5,473

6,066

6,553

6,838

7,590

8,787

9,140

Operating Profit

321

1,646

1,625

1,420

2,307

1,771

2,178

3,981

7,527

2,697

2,313

OPM %

9.94%

28.34%

26.91%

22.37%

29.66%

22.60%

24.95%

36.79%

49.79%

23.48%

20.20%

599

208

566

801

-97

621

1,154

931

2,729

2,511

Interest

234

135

278

391

489

483

448

Depreciation

251

293

358

429

451

479

489

504

524

561

583

Profit before Tax

642

1,497

1,741

1,558

1,688

1,164

2,032

4,240

7,445

4,382

4,363

Tax %

-3.07%

27.14%

17.31%

13.10%

12.57%

26.29%

24.75%

18.83%

22.43%

18.76%

19.44%

Net Profit

662

1,091

1,440

1,354

1,476

858

1,529

3,442

5,775

3,560

3,515

EPS

6.47

10.66

14.51

13.80

14.42

8.38

15.06

34.21

57.40

35.39

—

Dividend Payout %

49.51%

32.86%

24.89%

26.48%

24.28%

29.84%

39.71%

8.77%

19.16%

2.83%

—

Mar 2017

Mar 2018

Mar 2019

Mar 2020

Mar 2021

Mar 2022

Mar 2023

Mar 2024

Mar 2025

Mar 2026

Equity Capital

102

101

6,516

7,643

8,467

11,158

12,642

13,138

13,538

15,616

21,090

23,571

2,902

2,704

3,476

3,052

3,318

2,173

4,762

6,202

5,912

6,957

Trade Payables

996

803

701

863

1,126

1,065

1,043

1,112

1,232

1,472

1,316

1,997

2,328

2,981

2,898

3,447

3,641

4,466

8,703

6,910

Total Liabilities

11,832

13,249

15,074

18,156

20,086

19,925

23,086

27,496

37,037

39,011

2,352

2,680

3,932

4,109

4,112

4,336

4,184

4,369

4,202

5,084

Capital Work in Progress

678

659

675

553

570

384

739

627

1,188

621

3,924

3,618

4,195

6,404

6,471

5,118

4,879

7,283

11,492

11,478

933

1,321

1,472

1,395

1,780

1,926

1,782

1,687

1,952

2,178

4,740

8,162

8,495

Cash & Bank

184

112

385

154

303

248

414

144

734

3,928

4,787

4,687

5,310

6,999

7,859

11,253

8,376

9,897

10,421

Total Assets

11,832

13,249

15,074

18,156

20,086

19,925

23,086

27,496

37,037

39,011

Mar 2017

Mar 2018

Mar 2019

Mar 2020

Mar 2021

Mar 2022

Mar 2023

Mar 2024

Mar 2025

Mar 2026

975

583

893

1,382

2,491

1,542

1,471

2,000

3,114

2,234

Cash from Investing

-2,480

-745

-2,714

586

-1,959

-1,832

-4,504

570

Cash from Financing

1,366

-149

-967

255

-1,710

827

-301

1,384

-2,580

-247

167

-100

269

-231

149

-54

-132

-5

224

Mar 2017

Mar 2018

Mar 2019

Mar 2020

Mar 2021

Mar 2022

Mar 2023

Mar 2024

Mar 2025

Mar 2026

Jun 2024

Sep 2024

Dec 2024

Mar 2025

Jun 2025

Sep 2025

Dec 2025

Mar 2026

Jun 2026

74.98

74.99

75.00

75.01

5.59

7.52

7.53

7.31

7.13

7.34

7.06

6.95

6.88

12.56

10.59

10.61

10.95

11.09

10.86

11.08

11.20

11.27

Government

0.00

6.79

6.85

6.84

6.68

6.74

6.80

6.85

6.86

6.83

Zydus Lifesciences Ltd.

AI Sector View

Peer comparison

Quarterly Results

Profit & Loss

Balance Sheet

Corporate actions

Cash Flows

Ratios

Shareholding Pattern

Documents

News

Sign in to Chat with AI

Zydus Lifesciences Ltd.

AI Sector View

Peer comparison

Quarterly Results

Profit & Loss

Balance Sheet

Corporate actions

Cash Flows

Ratios

Shareholding Pattern

Documents

News

Sign in to Chat with AI